Preliminary CommunicationsA NEW ADRENERGIC: BETA-RECEPTOR ANTAGONIST
References (8)
- et al.
Lancet
(1962) - et al.
Brit. med. J.
(1963) - et al.
Brit. med. J.
(1963) - et al.
Brit. med. J.
(1963)
There are more references available in the full text version of this article.
Cited by (250)
Controlling intrusive thoughts of future fears under stress
2023, Neurobiology of StressCardiothoracic Anesthesia and Critical Care in the United Kingdom (UK) Part 1: Some Insights Into the History and Development
2021, Journal of Cardiothoracic and Vascular AnesthesiaCitation Excerpt :The current mainstay of pharmacologic therapy in heart failure, beta-adrenoreceptor blocking agents and angiotensin-converting enzyme inhibitors, owe their origins to the UK. In 1964, the beta-adrenoceptor blocking agent, propranolol, was synthesized by Black et al at Imperial Chemical Industries in Macclesfield, UK.66 This, together with subsequent compounds, also became one of the mainstays of therapy for hypertension.
Copyright © 1964 Published by Elsevier Ltd.